PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches

Small cell lung cancer (SCLC) is a very aggressive, highly lethal, neuroendocrine tumor that constitutes 15% of all lung cancer cases. It is characterized by its rapid disease progression and high relapse rate leading to poor survival for diagnosed patients. Recently, poly (ADP-ribose) polymerase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Barayan, Ranya, Ran, Xiaozhuo, Lok, Benjamin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Small Cell Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656434/
https://www.ncbi.nlm.nih.gov/pubmed/33209463
http://dx.doi.org/10.21037/jtd.2020.03.89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656434/
https://www.ncbi.nlm.nih.gov/pubmed/33209463
http://dx.doi.org/10.21037/jtd.2020.03.89

Ejemplares similares